--FILE--un cliente negozi per una stecca di Dumex baby formula di Danone in un supermercato a Yichang city, porcellane centrale provincia di Hubei, 24 settembre 20
--FILE--A customer shops for a carton of Dumex baby formula of Danone at a supermarket in Yichang city, central Chinas Hubei province, 24 September 2013. Chinas health regulators are rolling out a corporate blacklist for drug and medical-device companies implicated in commercial bribery, a move aimed at stamping out corruption in the countrys graft-ridden health-care sector. Beginning in March, the National Health and Family Planning Commission will publish on its website a record of medical-related manufacturers, agencies and individuals charged with bribery by courts, and sued, punished or investigated for bribery, the commission said in a statement on its website Friday (27 December 2013). Listed companies will be barred for two years from selling their products within the province in which they are implicated, the statement said. It said companies can apply as usual to sell their products in other provinces but will be at a disadvantage. Companies listed twice in a five-year period will be banned nationally for two years, the statement said. The developments come amid a heightened state of scrutiny of Chinas health-care industry. The Ministry of Public Security in July accused U.K. drug company GlaxoSmithKline PLC of bribing doctors, hospitals and government officials in an effort to sell more drugs at higher prices. Glaxo has said it appears some of its managers in China might have broken the law, and says it is cooperating with the probe. French food giant Danone SAs baby-food arm Dumex Baby Food Co. announced in October it would overhaul management and marketing at its infant formula business in China following allegations by the official China Central Television that it paid hospital staff to use its products and boost sales.
